Zimmer Biomet Holdings Inc (NYSE:ZBH) – Equities researchers at Jefferies Group lowered their Q2 2018 earnings per share (EPS) estimates for Zimmer Biomet in a research report issued on Thursday. Jefferies Group analyst R. Denhoy now anticipates that the medical equipment provider will post earnings per share of $1.92 for the quarter, down from their prior forecast of $1.95. Jefferies Group currently has a “Buy” rating and a $136.00 target price on the stock. Jefferies Group also issued estimates for Zimmer Biomet’s Q4 2018 earnings at $2.22 EPS.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the business posted $1.79 earnings per share.
Zimmer Biomet (NYSE ZBH) opened at $120.12 on Friday. The company has a market cap of $24,360.00, a P/E ratio of 37.42, a P/E/G ratio of 1.86 and a beta of 1.15. Zimmer Biomet has a fifty-two week low of $101.43 and a fifty-two week high of $133.49. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88.
The company also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s payout ratio is 29.91%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Ingalls & Snyder LLC lifted its holdings in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after acquiring an additional 507 shares during the last quarter. Private Advisor Group LLC raised its position in Zimmer Biomet by 18.6% in the 3rd quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after purchasing an additional 1,057 shares during the period. Koch Industries Inc. raised its position in Zimmer Biomet by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares during the period. Jensen Investment Management Inc. raised its position in Zimmer Biomet by 24.2% in the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock worth $751,000 after purchasing an additional 1,140 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Zimmer Biomet by 10.0% in the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after purchasing an additional 1,494 shares during the period. 85.92% of the stock is owned by institutional investors.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.